What is Prime Medicine's stock-based comp?

Prime Medicine (PRME) reported stock-based comp of $4.64M in Q1 2026.

How has Prime Medicine's stock-based comp changed year-over-year?

Prime Medicine's stock-based comp decreased by 18.3% year-over-year, from $5.68M to $4.64M.

What is the long-term trend for Prime Medicine's stock-based comp?

Over 3 years (2022 to 2025), Prime Medicine's stock-based comp has grown at a 65.5% compound annual growth rate (CAGR), from $6.46M to $29.27M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Prime Medicine PRME Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

Vertex PharmaceuticalsVRTX

$166.4M+0.2%

Intellia TherapeuticsNTLA

$13.48M-38.3%

CRISPR TherapeuticsCRSP

$16.32M-19.2%

Beam TherapeuticsBEAM

$19.04M-28.6%

RegenxbioRGNX

$8.62M+0.9%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's stock-based comp?: Prime Medicine (PRME) reported stock-based comp of $4.64M in Q1 2026.
How has Prime Medicine's stock-based comp changed year-over-year?: Prime Medicine's stock-based comp decreased by 18.3% year-over-year, from $5.68M to $4.64M.
What is the long-term trend for Prime Medicine's stock-based comp?: Over 3 years (2022 to 2025), Prime Medicine's stock-based comp has grown at a 65.5% compound annual growth rate (CAGR), from $6.46M to $29.27M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.